Advertisement
| companies developing car t therapies: Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book Daniel W. Lee, Nirali N. Shah, 2019-11-30 From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy. |
| companies developing car t therapies: Guidelines for Preparing Patent Landscape Reports World Intellectual Property Organization, 2015-08-24 These Guidelines are designed both for general users of patent information, as well as for those involved in producing Patent Landscape Reports (PLRs). They provide step-by-step instructions on how to prepare a PLR, as well as background information such as objectives, patent analytics, concepts and frameworks. |
| companies developing car t therapies: The EBMT/EHA CAR-T Cell Handbook Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele, 2022-02-07 This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills. |
| companies developing car t therapies: Immunopharmacogenomics Yusuke Nakamura, 2015-09-18 This book proposes immunogenomics, or immunopharmacogenomics, as the next-generation big science to uncover the role that the immune system plays in the pathogenesis of many diseases, by summarizing the importance of the deep sequencing of T-cell and B-cell receptors. Immunogenomics/immunopharmacogenomics, a genetic characterization of the immune system made possible by next-generation sequencing (NGS), will be important for the further understanding of the pathogenesis of various disease conditions. Abnormal immune responses in the body lead to development of autoimmune diseases and food allergies. Rejection of recipient cells and tissues, as well as severe immune reactions to donor cells, is also the result of uncontrolled immune responses in the recipient body. There have been many reports indicating that activated immune responses caused by the interaction of drugs and HLA are present in drug-induced skin hypersensitivity and liver toxicity. The importance of the host immune responses has been recognized in cancer treatments, not only for immunotherapy but also for cytotoxic agents and molecular targeted drugs. Hence, characterization of the T-cell receptor and B-cell receptor repertoire by means of NGS deep sequencing will ultimately make possible the identification of the molecular mechanisms that underlie various diseases and drug responses. In addition, this approach may contribute to the identification of antigens associated with the onset or progression of autoimmune diseases as well as food allergies. Although the germline alterations and somatic mutations have been extensively analyzed, changes or alterations of the immune responses during the course of various disease conditions or during various treatments have not been analyzed. It is also clear that computational analyses to draw meaningful inferences of functional recognition receptors on the immune cells remain a huge challenge. |
| companies developing car t therapies: Cell and Gene Therapies Miguel-Angel Perales, Syed A. Abutalib, Catherine Bollard, 2018-11-27 In this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, including hematopoietic transplant physicians, with information that is relevant to clinical practice and ongoing research. Each chapter focuses on a particular topic, and the concise text is supported by numerous working tables, algorithms, and figures. Whenever appropriate, guidance is provided regarding the availability of potentially high-impact clinical trials. The rapid evolution of cell and gene therapies is giving rise to numerous controversies that need to be carefully addressed. In meeting this challenge, this book will appeal to all residents, fellows, and faculty members responsible for the care of hematopoietic cell transplant patients. It will also offer a robust, engaging tool to aid vital activities in the daily work of every hematology and oncology trainee. |
| companies developing car t therapies: The Business of Healthcare Innovation Lawton Robert Burns, 2005-08-25 The Business of Healthcare Innovation is the first wide-ranging analysis of business trends in the manufacturing segment of the health care industry. In this leading edge volume, Professor Burns focuses on the key role of the 'producers' as the main source of innovation in health systems. Written by professors of the Wharton School and industry executives, this book provides a detailed overview of the pharmaceutical, biotechnology, genomics/proteomics, medical device and information technology sectors. It analyses the market structures of these sectors as well as the business models and corporate strategies of firms operating within them. Most importantly, the book describes the growing convergence between these sectors and the need for executives in one sector to increasingly draw upon trends in the others. It will be essential reading for students and researchers in the field of health management, and of great interest to strategy scholars, industry practitioners and management consultants. |
| companies developing car t therapies: Protein Engineering Huimin Zhao, 2021-08-23 A one-stop reference that reviews protein design strategies to applications in industrial and medical biotechnology Protein Engineering: Tools and Applications is a comprehensive resource that offers a systematic and comprehensive review of the most recent advances in the field, and contains detailed information on the methodologies and strategies behind these approaches. The authors—noted experts on the topic—explore the distinctive advantages and disadvantages of the presented methodologies and strategies in a targeted and focused manner that allows for the adaptation and implementation of the strategies for new applications. The book contains information on the directed evolution, rational design, and semi-rational design of proteins and offers a review of the most recent applications in industrial and medical biotechnology. This important book: Covers technologies and methodologies used in protein engineering Includes the strategies behind the approaches, designed to help with the adaptation and implementation of these strategies for new applications Offers a comprehensive and thorough treatment of protein engineering from primary strategies to applications in industrial and medical biotechnology Presents cutting edge advances in the continuously evolving field of protein engineering Written for students and professionals of bioengineering, biotechnology, biochemistry, Protein Engineering: Tools and Applications offers an essential resource to the design strategies in protein engineering and reviews recent applications. |
| companies developing car t therapies: Exploring Novel Clinical Trial Designs for Gene-Based Therapies National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Forum on Regenerative Medicine, 2020-08-27 Recognizing the potential design complexities and ethical issues associated with clinical trials for gene therapies, the Forum on Regenerative Medicine of the National Academies of Sciences, Engineering, and Medicine held a 1-day workshop in Washington, DC, on November 13, 2019. Speakers at the workshop discussed patient recruitment and selection for gene-based clinical trials, explored how the safety of new therapies is assessed, reviewed the challenges involving dose escalation, and spoke about ethical issues such as informed consent and the role of clinicians in recommending trials as options to their patients. The workshop also included discussions of topics related to gene therapies in the context of other available and potentially curative treatments, such as bone marrow transplantation for hemoglobinopathies. This publication summarizes the presentation and discussion of the workshop. |
| companies developing car t therapies: Co-signal Molecules in T Cell Activation Miyuki Azuma, Hideo Yagita, 2019-11-22 This book equips young immunologists and health professionals with a clear understanding of the fundamental concepts and roles of co-signal molecules and in addition presents the latest information on co-stimulation. The first part of the book is devoted to co-signal molecules and the regulation of T cells. Following an initial overview, subsequent chapters examine each co-signal molecule in turn and discuss the mechanisms by which co-signal molecules regulate the different types of T cell. The second part covers various clinical applications, including in autoimmune disease, neurological disorders, transplantation, graft-versus-host disease, and cancer immunotherapy. To date, co-stimulation blockade and co-inhibition blockade have shown beneficial effects and many additional clinical trials targeting co-signal molecules are ongoing. The mechanisms underlying these successful treatments are explained and the future therapeutic potential in the aforementioned diseases is evaluated. Co-signal Molecules in T Cell Activation will be a valuable reference guide to co-stimulation for basic and clinical researchers in the fields of both immunology and pharmaceutical science. |
| companies developing car t therapies: Oncoimmunology Laurence Zitvogel, Guido Kroemer, 2017-12-13 In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field. |
| companies developing car t therapies: Quality Management and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy Mahmoud Aljurf, John A. Snowden, Patrick Hayden, Kim H. Orchard, Eoin McGrath, 2021-02-19 This open access book provides a concise yet comprehensive overview on how to build a quality management program for hematopoietic stem cell transplantation (HSCT) and cellular therapy. The text reviews all the essential steps and elements necessary for establishing a quality management program and achieving accreditation in HSCT and cellular therapy. Specific areas of focus include document development and implementation, audits and validation, performance measurement, writing a quality management plan, the accreditation process, data management, and maintaining a quality management program. Written by experts in the field, Quality Management and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy: A Practical Guide is a valuable resource for physicians, healthcare professionals, and laboratory staff involved in the creation and maintenance of a state-of-the-art HSCT and cellular therapy program. |
| companies developing car t therapies: Translational Regenerative Medicine Anthony Atala, Julie Allickson, 2014-12-01 Translational Regenerative Medicine is a reference book that outlines the life cycle for effective implementation of discoveries in the dynamic field of regenerative medicine. By addressing science, technology, development, regulatory, manufacturing, intellectual property, investment, financial, and clinical aspects of the field, this work takes a holistic look at the translation of science and disseminates knowledge for practical use of regenerative medicine tools, therapeutics, and diagnostics. Incorporating contributions from leaders in the fields of translational science across academia, industry, and government, this book establishes a more fluid transition for rapid translation of research to enhance human health and well-being. - Provides formulaic coverage of the landscape, process development, manufacturing, challenges, evaluation, and regulatory aspects of the most promising regenerative medicine clinical applications - Covers clinical aspects of regenerative medicine related to skin, cartilage, tendons, ligaments, joints, bone, fat, muscle, vascular system, hematopoietic /immune system, peripheral nerve, central nervous system, endocrine system, ophthalmic system, auditory system, oral system, respiratory system, cardiac system, renal system, hepatic system, gastrointestinal system, genitourinary system - Identifies effective, proven tools and metrics to identify and pursue clinical and commercial regenerative medicine |
| companies developing car t therapies: Haploidentical Transplantation Stefan O. Ciurea, Rupert Handgretinger, 2018-05-03 In this book, world-renowned experts in the field express well-reasoned opinions on a range of issues and controversies relating to haploidentical transplantation with the aim of providing practicing hematologists with clinically relevant and readily applicable information. Among the areas covered are graft manipulation and methods to control T-cell alloreactivity, the nature of the ideal graft and donor, haploidentical transplantation in pediatric and adult patients with malignant and nonmalignant diseases, immunologic reconstitution following transplantation, complications, and the prevention and treatment of relapse post transplantation. Attention is drawn to the implications of high-impact clinical trials whenever such trials are available. The readily intelligible text is complemented by numerous helpful tables, algorithms, and figures. The book will provide practical support for hematologists and transplant physicians as they attempt to provide optimal care in this exciting but increasingly complex medical specialty. |
| companies developing car t therapies: Current Strategies in Cancer Gene Therapy Wolfgang Walther, 2017-01-17 This book describes important developments and emerging trends in experimental and clinical cancer gene therapy. It reflects the tremendous advances made over recent years with respect to immunogenes, suicide genes and gene correction therapies, as well as in gene suppression and miRNA therapies. Many of the described strategies focus on the generation of more efficient and specific means of attack at known and novel cellular targets associated with tumor development and progression. The book also details parallel improvements in vector design, vector delivery, and therapeutic efficacy. It offers readers a stimulating, broad overview of advances in the field, linking experimental strategies to their clinical applications. |
| companies developing car t therapies: Blood and Marrow Transplant Handbook Richard T. Maziarz, Susan Schubach Slater, 2015-04-20 This updated and expanded edition developed by the Blood and Marrow Stem Cell Transplant team at Oregon Health & Science University Knight Cancer Institute features the latest medical management guidelines and standards of care for hematopoietic stem cell transplant patients. Spanning the timeline from the initial consultation throughout the transplant process, this handbook includes indications for transplantation and donor selection, treatment guidelines for addressing complications during and after transplant, and recommendations for long-term follow up care. Concise, comprehensive, and easy-to-use, Blood and Marrow Transplant Handbook, 2nd Edition presents a multidisciplinary approach to information for physicians and advanced practice medical providers who care for transplant patients, and also residents, fellows, and other trainees. |
| companies developing car t therapies: From Breakthrough to Blockbuster Donald L. Drakeman, Lisa N. Drakeman, Nektarios Oraiopoulos, 2022 Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive-- |
| companies developing car t therapies: Gene and Cellular Immunotherapy for Cancer Armin Ghobadi, John F. DiPersio, 2022-01-01 Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more. Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field. |
| companies developing car t therapies: Treatment of Leukemia and Lymphoma David A. Scheinberg, Joseph G. Jurcic, 2004-10-30 New Treatments of Leukemia and Lymphoma describes the most important advances in the therapy of hematopoietic cancers that have been derived from recent discoveries in cancer cell biology, kinase biochemistry, and immunology. Detailed descriptions of the large number of new and effective agents that have recently become available for the treatment of leukemias and lymphomas as well as an understanding of their mechanisms of action and their integration into current therapy are provided. A number of experimental drug reagents currently in clinical investigation are also discussed. The therapies include conventional anti-metabolites, monoclonal antibodies directed to cell surface receptors, antibodies tagged with toxins and radiopharmaceuticals, inhibitors of specific kinases, stem cell transplants, and engineered T-cells designed to selectively target hematopoietic cancers. The contents of the book will allow practitioners and investigators alike to understand what is current and state of the art as well as what to look for in the future.* Provides an up-to-date, state of the art discussion of a rapidly changing field * Great breadth covering conventional chemotherapeutic agents, biologic agents such as antibodies, novel small molecule inhibitors and genetically engineered cells * Written by international experts in each of the fields |
| companies developing car t therapies: The Role of NIH in Drug Development Innovation and Its Impact on Patient Access National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Board on Health Care Services, 2020-01-27 To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly hosted a public workshop on July 24â€25, 2019, in Washington, DC. Workshop speakers and participants discussed the ways in which federal investments in biomedical research are translated into innovative therapies and considered approaches to ensure that the public has affordable access to the resulting new drugs. This publication summarizes the presentations and discussions from the workshop. |
| companies developing car t therapies: The Greenhouse Gas Protocol , 2004 The GHG Protocol Corporate Accounting and Reporting Standard helps companies and other organizations to identify, calculate, and report GHG emissions. It is designed to set the standard for accurate, complete, consistent, relevant and transparent accounting and reporting of GHG emissions. |
| companies developing car t therapies: Ask a Manager Alison Green, 2018-05-01 'I'm a HUGE fan of Alison Green's Ask a Manager column. This book is even better' Robert Sutton, author of The No Asshole Rule and The Asshole Survival Guide 'Ask A Manager is the book I wish I'd had in my desk drawer when I was starting out (or even, let's be honest, fifteen years in)' - Sarah Knight, New York Times bestselling author of The Life-Changing Magic of Not Giving a F*ck A witty, practical guide to navigating 200 difficult professional conversations Ten years as a workplace advice columnist has taught Alison Green that people avoid awkward conversations in the office because they don't know what to say. Thankfully, Alison does. In this incredibly helpful book, she takes on the tough discussions you may need to have during your career. You'll learn what to say when: · colleagues push their work on you - then take credit for it · you accidentally trash-talk someone in an email and hit 'reply all' · you're being micromanaged - or not being managed at all · your boss seems unhappy with your work · you got too drunk at the Christmas party With sharp, sage advice and candid letters from real-life readers, Ask a Manager will help you successfully navigate the stormy seas of office life. |
| companies developing car t therapies: Encyclopedia of Biomedical Gerontology , 2019-11-20 Encyclopedia of Biomedical Gerontology, Three Volume Set presents a wide range of topics, ranging from what happens in the body during aging, the reasons and mechanisms relating to those age-related changes, and their clinical, psychological and social modulators and determinants. The book covers the biological and medical aspects of gerontology within the general framework of the biological basis of assessing age, biological mechanisms of aging, age-related changes in biological systems, human age-related diseases, the biomedical practicality and impracticality of interventions, and finally, the ethics of intervention. Provides a ‘one-stop’ resource to information written by world-leading scholars in the field of biomedical gerontology Fills a critical gap of information in a field that has seen significant progress in the last 10 years |
| companies developing car t therapies: Allocation of Staff , 1983 |
| companies developing car t therapies: Heparanase Israel Vlodavsky, Ralph D. Sanderson, Neta Ilan, 2020-04-09 Written by internationally recognized leaders in Heparanase biology, the book’s eight chapters offer an opportunity for scientists, clinicians and advanced students in cell biology, tumor biology and oncology to obtain a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications. Proteases and their involvement in cancer progression have been well addressed and documented; however, the emerging premise presented within this book is that Heparanase is a master regulator of aggressive cancer phenotypes and crosstalk with the tumor microenvironment. This endoglycosidase contributes to tumor-mediated remodeling of the extracellular matrix and cell surfaces, augmenting the bioavailability of pro-tumorigenic and pro-inflammatory growth factors and cytokines that are bound to Heparan sulfate. Compelling evidence ties Heparanase with all steps of tumor progression including tumor initiation, growth, angiogenesis, metastasis, and chemoresistance, supporting the notion that Heparanase is an important contributor to the poor outcome of cancer patients and a validated target for therapy. Unlike Heparanase, heparanase-2, a close homolog of Heparanase, lacks enzymatic activity, inhibits Heparanase, and regulates selected genes that promote normal differentiation and tumor suppression. Written by internationally recognized leaders in Heparanase biology, this volume presents a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications to scientists, clinicians and advanced students in cell biology, tumor biology and oncology. |
| companies developing car t therapies: Global Trends 2040 National Intelligence Council, 2021-03 The ongoing COVID-19 pandemic marks the most significant, singular global disruption since World War II, with health, economic, political, and security implications that will ripple for years to come. -Global Trends 2040 (2021) Global Trends 2040-A More Contested World (2021), released by the US National Intelligence Council, is the latest report in its series of reports starting in 1997 about megatrends and the world's future. This report, strongly influenced by the COVID-19 pandemic, paints a bleak picture of the future and describes a contested, fragmented and turbulent world. It specifically discusses the four main trends that will shape tomorrow's world: - Demographics-by 2040, 1.4 billion people will be added mostly in Africa and South Asia. - Economics-increased government debt and concentrated economic power will escalate problems for the poor and middleclass. - Climate-a hotter world will increase water, food, and health insecurity. - Technology-the emergence of new technologies could both solve and cause problems for human life. Students of trends, policymakers, entrepreneurs, academics, journalists and anyone eager for a glimpse into the next decades, will find this report, with colored graphs, essential reading. |
| companies developing car t therapies: Report to the Congress, Medicare Payment Policy Medicare Payment Advisory Commission (U.S.), 1998 |
| companies developing car t therapies: Principles of Translational Science in Medicine Martin Wehling, 2015-04-02 Principles of Translational Science in Medicine: From Bench to Bedside, Second Edition, provides an update on major achievements in the translation of research into medically relevant results and therapeutics. The book presents a thorough discussion of biomarkers, early human trials, and networking models, and includes institutional and industrial support systems. It also covers algorithms that have influenced all major areas of biomedical research in recent years, resulting in an increasing numbers of new chemical/biological entities (NCEs or NBEs) as shown in FDA statistics. The book is ideal for use as a guide for biomedical scientists to establish a systematic approach to translational medicine. - Provides an in-depth description of novel tools for the assessment of translatability of trials to balance risk and improve projects at any given stage of product development - New chapters deal with translational issues in the fastest growing population (the elderly), case studies, translatability assessment tools, and advances in nanotherapies - Details IPR issues of translation, especially for public-private-partnerships - Contains contributions from world leaders in translational medicine, including the former NIH director and authorities from various European regulatory institutions |
| companies developing car t therapies: Praying for Emily Tom Whitehead, Kari Whitehead, Emily Whitehead, 2020-10-06 Discover the incredible true story of Emily Whitehead, the first child to receive CAR-T cell treatment for her leukemia -- and learn how her family's faith journey guided them in the fight for her life. When their five-year-old daughter was diagnosed with leukemia, Tom and Kari Whitehead's world was shattered. They vowed to do whatever it took to help their daughter, and as they made decisions about how to best treat her, Tom found his faith coming to him in whispers, guiding his decisions and keeping his hope alive, while Kari placed great faith in science and the doctors surrounding her little girl. But as Emily's condition continued to worsen, they both prayed for a miracle. Then, their miracle arrived, in the form of an experimental treatment called CAR-T cell therapy that, against all odds, saved Emily's life. Because of Emily's miraculous recovery, this treatment is now used widely to treat cancer and has gone on to save hundreds of lives and promises to help thousands more. For all the acclaim and attention this important new approach to treating cancer has received, few know the full story of all it took to make this miracle happen. In Praying for Emily, the Whiteheads share their story, recounting the belief, resilience, and support that got them through the most difficult time of their lives. |
| companies developing car t therapies: Bioreactor Systems for Tissue Engineering Cornelia Kasper, Martijn van Griensven, Ralf Pörtner, 2009-02-03 The editors of this special volume would first like to thank all authors for their excellent contributions. We would also like to thank Prof. Dr. Thomas Scheper, Dr. Marion Hertel and Ulrike Kreusel for providing the opportunity to compose this volume and Springer for organizational and technical support. Tissue engineering represents one of the major emerging fields in modern b- technology; it combines different subjects ranging from biological and material sciences to engineering and clinical disciplines. The aim of tissue engineering is the development of therapeutic approaches to substitute diseased organs or tissues or improve their function. Therefore, three dimensional biocompatible materials are seeded with cells and cultivated in suitable systems to generate functional tissues. Many different aspects play a role in the formation of 3D tissue structures. In the first place the source of the used cells is of the utmost importance. To prevent tissue rejection or immune response, preferentially autologous cells are now used. In particular, stem cells from different sources are gaining exceptional importance as they can be differentiated into different tissues by using special media and supplements. In the field of biomaterials, numerous scaffold materials already exist but new composites are also being developed based on polymeric, natural or xenogenic sources. Moreover, a very important issue in tissue en- neering is the formation of tissues under well defined, controlled and reprod- ible conditions. Therefore, a substantial number of new bioreactors have been developed. |
| companies developing car t therapies: The Green Book Great Britain. Treasury, 2003 This new edition incorporates revised guidance from H.M Treasury which is designed to promote efficient policy development and resource allocation across government through the use of a thorough, long-term and analytically robust approach to the appraisal and evaluation of public service projects before significant funds are committed. It is the first edition to have been aided by a consultation process in order to ensure the guidance is clearer and more closely tailored to suit the needs of users. |
| companies developing car t therapies: Cancer Cell Lines Part 1 John Masters, Bernhard Ø Palsson, 2006-04-11 Continuous cell lines derived from human cancers are the most widely used resource in laboratory-based cancer research. The first 3 volumes of this series on Human Cell Culture are devoted to these cancer cell lines. The chapters in these first 3 volumes have a common aim. Their purpose is to address 3 questions of fundamental importance to the relevance of human cancer cell lines as model systems of each type of cancer: 1. Do the cell lines available accurately represent the clinical presentation? 2. Do the cell lines accurately represent the histopathology of the original tumors? 3. Do the cell lines accurately represent the molecular genetics of this type of cancer? The cancer cell lines available are derived, in most cases, from the more aggressive and advanced cancers. There are few cell lines derived from low grade organ-confined cancers. This gap can be filled with conditionally immortalized human cancer cell lines. We do not know why the success rate for establishing cell lines is so low for some types of cancer and so high for others. The histopathology of the tumor of origin and the extent to which the derived cell line retains the differentiated features of that tumor are critical. The concept that a single cell line derived from a tumor at a particular site is representative of tumors at that site is naïve and misleading. |
| companies developing car t therapies: Principles and Practice of Pediatric Oncology Philip A. Pizzo, 2011 Thoroughly updated for its Sixth Edition,Principles and Practice of Pediatric Oncologyprovides a comprehensive review of the multiple disciplines that make up the care and research agendas for children with cancer. It is the most comprehensive textbook of pediatric oncology ever put together, covering biology and genetics and detailing the diagnosis, multimodal treatment, and long-term management of patients with cancer. The fundamental principles of supportive care and the psychosocial aspects of support for patients and families are also discussed. |
| companies developing car t therapies: Developing Costimulatory Molecules for Immunotherapy of Diseases Manzoor Ahmad Mir, 2015-05-25 Developing Costimulatory Molecules for Immunotherapy of Diseases highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy using either humanized antibodies against CD80, CD86, and other costimulatory molecules or CD28 fusinogenic proteins in the treatment of diseases, including allergies, asthma, rheumatoid arthritis, multiple sclerosis, lupus nephritis, severe psoriasis, vulgaris tuberculosis, thopoid, transplantation therapeutic, cancer, and inflammation. The text aims to provide the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families, with the hope that targeting these families will yield new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases. - Highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy - Provides the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families - Targets new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases |
| companies developing car t therapies: Cancer Immunology and Immunotherapy Mansoor M. Amiji, Lara Scheherazade Milane, 2021-08-18 Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches. Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. - Comprehensive treaty covering all aspects of immuno-oncology (IO) - Novel strategies for delivery of IO therapeutics and vaccines - Forecasting on the future of nanotechnology and drug delivery for IO |
| companies developing car t therapies: Ex Vivo Cell Therapy Klaus Schindhelm, Robert Nordon, 1999 R.E. Nordon and K. Schindhelm, Introduction. -- L. Robb, A.G. Elefanty, and C.G. Begley, Transcriptional Control of Hematopoieses. -- R. Starr and N.A. Nicola, Cell Signaling by Hemopoietic Growth Factor Receptors. -- P.J. Simmons, D.N. Haylock, and J.-P. Lévesque, Influence of Cytokines and Adhesion Molecules on Hematopoietic Stem Cell Development. -- P.A. Rowlings, Allogeneic Hematopoietic Stem Cell Transplantation. -- U. Hahn and L.B. To, Autologous Stem Cell Transplantation. -- M.R. Vowels, Cord Blood Stem Cell Transplantation. -- S.R. Riddell, E.H. Warren, D. Lewinsohn, C. Yee, and P.D. Greenberg, Reconstitution of Immunity by Adoptive Immunotherapy with T Cells. -- L.Q. Sun, M. Miller, and G. Symonds, Exogenous Gene Transfer into Lymphoid and Hematopoietic Progenitor Cells. -- C. Dowding, T. Leemhuis, A. Jakubowski, and C. Reading, Process Development for Ex Vivo Cell Therapy. -- R.E. Nordon and K. Schindhelm, Cell Separation. -- P.W. Zandstra, C.J. Eaves, and J.M. Piret, Environ ... |
| companies developing car t therapies: Artificial Intelligence Harvard Business Review, 2019 Companies that don't use AI to their advantage will soon be left behind. Artificial intelligence and machine learning will drive a massive reshaping of the economy and society. What should you and your company be doing right now to ensure that your business is poised for success? These articles by AI experts and consultants will help you understand today's essential thinking on what AI is capable of now, how to adopt it in your organization, and how the technology is likely to evolve in the near future. Artificial Intelligence: The Insights You Need from Harvard Business Review will help you spearhead important conversations, get going on the right AI initiatives for your company, and capitalize on the opportunity of the machine intelligence revolution. Catch up on current topics and deepen your understanding of them with the Insights You Need series from Harvard Business Review. Featuring some of HBR's best and most recent thinking, Insights You Need titles are both a primer on today's most pressing issues and an extension of the conversation, with interesting research, interviews, case studies, and practical ideas to help you explore how a particular issue will impact your company and what it will mean for you and your business. |
| companies developing car t therapies: Biopharma in China Sven Agten, |
| companies developing car t therapies: Stem Cell Manufacturing Joaquim M.S. Cabral, Claudia Lobato da Silva, Lucas G. Chase, M. Margardia Diogo, 2016-07-24 Stem Cell Manufacturing discusses the required technologies that enable the transfer of the current laboratory-based practice of stem cell tissue culture to the clinic environment as therapeutics, while concurrently achieving control, reproducibility, automation, validation, and safety of the process and the product. The advent of stem cell research unveiled the therapeutic potential of stem cells and their derivatives and increased the awareness of the public and scientific community for the topic. The successful manufacturing of stem cells and their derivatives is expected to have a positive impact in the society since it will contribute to widen the offer of therapeutic solutions to the patients. Fully defined cellular products can be used to restore the structure and function of damaged tissues and organs and to develop stem cell-based cellular therapies for the treatment of cancer and hematological disorders, autoimmune and other inflammatory diseases and genetic disorders. - Presents the first 'Flowchart' of stem cell manufacturing enabling easy understanding of the various processes in a sequential and coherent manner - Covers all bioprocess technologies required for the transfer of the bench findings to the clinic including the process components: cell signals, bioreactors, modeling, automation, safety, etc. - Presents comprehensive coverage of a true multidisciplinary topic by bringing together specialists in their particular area - Provides the basics of the processes and identifies the issues to be resolved for large scale cell culture by the bioengineer - Addresses the critical need in bioprocessing for the successful delivery of stem cell technology to the market place by involving professional engineers in sections of the book |
| companies developing car t therapies: Childhood Cancer and Functional Impacts Across the Care Continuum National Academies of Sciences Engineering and Medicine, Health and Medicine Division, Board on Health Care Services, Committee on Childhood Cancers and Disability, 2021-09-09 Since the late 1960s, the survival rate in children and adolescents diagnosed with cancer has steadily improved, with a corresponding decline in the cancer-specific death rate. Although the improvements in survival are encouraging, they have come at the cost of acute, chronic, and late adverse effects precipitated by the toxicities associated with the individual or combined use of different types of treatment (e.g., surgery, radiation, chemotherapy). In some cases, the impairments resulting from cancer and its treatment are severe enough to qualify a child for U.S. Social Security Administration disability benefits. At the request of Social Security Administration, Childhood Cancer and Functional Impacts Across the Care Continuum provides current information and findings and conclusions regarding the diagnosis, treatment, and prognosis of selected childhood cancers, including different types of malignant solid tumors, and the effect of those cancers on childrenâ (TM)s health and functional capacity, including the relative levels of functional limitation typically associated with the cancers and their treatment. This report also provides a summary of selected treatments currently being studied in clinical trials and identifies any limitations on the availability of these treatments, such as whether treatments are available only in certain geographic areas. |
| companies developing car t therapies: Gene and Cell Therapy Nancy Smyth Templeton, 2003-12-17 This reference is completely revised and expanded to reflect the most critical studies, controversies, and technologies impacting the medical field, including probing research on lentivirus, gutless adenovirus, bacterial and baculovirus vectors, retargeted viral vectors, in vivo electroporation, in vitro and in vivo gene detection systems, and all inducible gene expression systems. Scrutinizing every tool, technology, and issue impacting the future of gene and cell research, it is specifically written and organized for laymen, scholars, and specialists from varying backgrounds and disciplines to understand the current status of gene and cell therapy and anticipate future developments in the field. |
Business English- Describing Companies - UsingEnglish.com
Describing companies from different countries Choose a company below that you know quite well and describe it until your partner guesses which one you are talking about. Then discuss if …
the company have or the company has - UsingEnglish.com
Feb 14, 2016 · I have a question: What is the correct sentance? The company have 200 employees. The company has 200 employess.
present simple and continuous describing company and job
We are trying to cut costs compared to last year by moving more production abroad. We provide language training to big and small companies in 34 countries around the world. We make …
Business English- Describing Companies with the Present Simple …
Describing companies with Present Simple and Continuous Try to describe your company by completing some of the sentences below, starting with any you like. Your partner will then …
describing your company and job longer speaking
I sell insurance to companies. – I sell liability insurance etc to SMEs, which stands for small and medium-sized enterprises. I work in HR. – I work in the HR department of an American …
The 100 most useful phrases for business meetings
Oct 15, 2023 · The most useful phrases for the beginning of meetings Ending the small talk and getting down to business phrases Dealing with practicalities of the meeting The most useful …
Companie's vs. Company's | UsingEnglish.com ESL Forum
Apr 16, 2007 · 1 company- the company's figures 2 or more copmpanies- the companies' figures Companie's- :cross: Not open for further replies.
[Vocabulary] - A person who serves drinks and food
Aug 11, 2015 · How do we call a person whose job is to make coffee, tea, etc. and to serve these drinks to employees and guests in factories, offices, and companies...
List of regular plurals ending in -s, -es and -ies
Apr 15, 2024 · The big list of regular plurals ending in -s, -es and -ies, arranged by level Most nouns in English simply take -s to make a plural, without adding any other extra sounds or …
Is a company a "she" or "It" | UsingEnglish.com ESL Forum
Dec 20, 2012 · i need to write a contract for my company , i need to know if a company is a "She/Her" or "it". for example: "Circumstances that are beyond her control" or "Circumstances …
Business English- Describing Companies - UsingEnglish.com
Describing companies from different countries Choose a company below that you know quite well and describe it until your partner guesses which one you are talking about. Then discuss if …
the company have or the company has - UsingEnglish.com
Feb 14, 2016 · I have a question: What is the correct sentance? The company have 200 employees. The company has 200 employess.
present simple and continuous describing company and job
We are trying to cut costs compared to last year by moving more production abroad. We provide language training to big and small companies in 34 countries around the world. We make …
Business English- Describing Companies with the Present Simple …
Describing companies with Present Simple and Continuous Try to describe your company by completing some of the sentences below, starting with any you like. Your partner will then …
describing your company and job longer speaking
I sell insurance to companies. – I sell liability insurance etc to SMEs, which stands for small and medium-sized enterprises. I work in HR. – I work in the HR department of an American …
The 100 most useful phrases for business meetings
Oct 15, 2023 · The most useful phrases for the beginning of meetings Ending the small talk and getting down to business phrases Dealing with practicalities of the meeting The most useful …
Companie's vs. Company's | UsingEnglish.com ESL Forum
Apr 16, 2007 · 1 company- the company's figures 2 or more copmpanies- the companies' figures Companie's- :cross: Not open for further replies.
[Vocabulary] - A person who serves drinks and food
Aug 11, 2015 · How do we call a person whose job is to make coffee, tea, etc. and to serve these drinks to employees and guests in factories, offices, and companies...
List of regular plurals ending in -s, -es and -ies
Apr 15, 2024 · The big list of regular plurals ending in -s, -es and -ies, arranged by level Most nouns in English simply take -s to make a plural, without adding any other extra sounds or …
Is a company a "she" or "It" | UsingEnglish.com ESL Forum
Dec 20, 2012 · i need to write a contract for my company , i need to know if a company is a "She/Her" or "it". for example: "Circumstances that are beyond her control" or "Circumstances …
